Peter Allen ACA
Chairman of the Board
Peter Allen joined the board of Oxford Nanopore in 2011, bringing broad, senior experience in the life sciences industries. He currently serves as Chairman on the Boards of Clinigen Group (AIM listed), AMS (AIM listed), Diurnal (AIM listed) and Non-Executive Chairman on the Board of Istesso.
Previously, Peter was Chief Financial Officer of the electronics company Abacus Group plc from April 2005 until the company was sold to Avnet Inc in January 2009. Prior to this he was Chief Financial Officer of Celltech Group plc between 1992 and 2004. In addition to managing Celltech's flotation process in 1993, Peter played a key role in several strategic acquisitions, including Chiroscience Group plc, Medeva plc and Oxford Glycosciences plc. In 2003 Peter was also appointed Deputy Chief Executive Officer of Celltech until the company was sold to UCB in 2004.
Sarah Gordon Wild
Sarah Gordon Wild worked as a biotechnology analyst from 1983-2003. She was based on Wall Street for over 15 years and was a Management Committee Member and Senior Healthcare Analyst at Lone Pine Capital LLC from 1998 to 2003. She continues to serve on the Board of Lone Pine Capital Offshore Funds. She currently serves as a NED for Evox Therapeutics and Redx Pharma PLC and is a Partner at Duke’s Auctioneers Ltd.
John O’Higgins was previously CEO of Spectris, the international productivity-enhancing instrumentation and controls company, where he led rapid global growth and evolution of the company as it pursued multiple market applications from a broad technology platform.
John holds several non-executive roles including at the global science and chemicals company Johnson Matthey plc, whose solutions are designed to enable cleaner air, improved health and the more efficient use of natural resources. He also served as a non-executive Director of Exide Technologies, the US-based supplier of battery technology to automotive and industrial users.
John is also a Member of the Corporate Advisory Board of Great Ormond Street Hospital Charity in the UK.
Dr Guy Harmelin
Non executive director
Dr Guy Harmelin has extensive experience in healthcare and technology investment and entrepreneurship. Guy was previously on the leadership team at Harel Insurance Investments and Financial Services, the largest insurance group in Israel with over $71 billion in assets under management. Guy has invested and worked with multiple successful companies including Lemonade, Innoviz, American Well, Ecoppia, Ayala Pharma, Biond Biologics, Tabit, Assured Allies, Quantum Machines, Rafael and Ein-Tal Hospitals.
Prior to joining Harel, Guy was the Co-Founder and CEO of RondinX, a computational drug target discovery Company which merged with BiomX and went public on NYSE in November 2019, PHGE.
Guy has an MD Summa Cum Laude from the University of Florence and served as a Resident Physician at the Tel Aviv Medical Center.
Alan is the Chief Executive Officer of IP Group plc, a company that invests in and builds technology businesses based on intellectual property, primarily from its research intensive partner universities. IP Group offers more than traditional venture capital, providing its companies with access to business building expertise, capital, networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across four main sectors -- Biotech, Cleantech, Healthcare and Technology. The Company is listed on the Main Market of the London Stock Exchange under the code IPO.
Alan was the joint founder and Chief Executive of Techtran Group Ltd, the first company in Europe to offer a complete outsourced technology transfer function to universities. Techtran was acquired by IP Group in 2005. Alan is also Non-Executive Chairman of Proactis, an AIM-listed software company based in York and Non-executive Director of Oxford Sciences Innovation plc. From 1995-2002 Alan was a partner in KPMG where he specialised in providing advice to fast growing technology businesses. Alan holds a BA in Economics from the University of Leeds and a MBA with Distinction from the University of Bradford. He is a fellow of the Institute of Chartered Accountants of England and Wales.
Non executive Director
Wendy Becker is an experienced international, public company Board director. She is currently Chair of the global technology business Logitech International SA, a Non-executive Director of Sony Corporation and a member of the Council of the University of Oxford. She previously served on a number of boards including NHS England and Cancer Research UK. In her successful executive career, she held a number of general management, digital and marketing, and strategy roles. Wendy was CEO of Jack Wills, the British-based clothing manufacturer and retailer as well as Global CMO of Vodafone, the Managing Director of TalkTalk, and a partner at McKinsey & Company.
Non executive Director
Adrian is a highly regarded business leader with nearly 20 years’ leadership experience at a number of FTSE 100 companies. His background encompasses a breadth of sectors including healthcare, technology, FMCG and engineering. Adrian was Chief Financial Officer at Reckitt Benckiser for seven years and held the same role at both Smith & Nephew and Invensys. He spent 18 years at GlaxoSmithKline, holding a number of senior management and financial positions. Adrian began his career at PwC, working in both audit and consultancy, and Stadtsparkasse Koeln, the German regional bank. Adrian currently serves on the Board of Sainsbury’s, where he is a member of the Audit and Nomination Committees, and Oxford University Press.
Dr Gordon Sanghera
Chief Executive Officer
Gordon Sanghera was co-founder of Oxford Nanopore, together with Hagan Bayley and IP Group. He was appointed CEO in June 2005. He brings over 20 years' experience in the design, development and global launch of disruptive platform sensor technologies.
Dr Sanghera’s PhD in bioelectronics sensing was followed by a career at MediSense an Oxford spin-out that delivered a new generation glucose technology to the market. Following the acquisition of MediSense by Abbott Laboratories Dr Sanghera held both UK and US VP and Director-level positions, including VP World Wide Marketing, Research Director and Manufacturing Process Development Director. Before its acquisition by Abbott, Gordon led the R&D of Medisense Inc. where he was instrumental in the launch of several generations of blood glucose bio-electronic systems for the consumer and hospital medical markets. He has also developed and validated production processes to meet with the regulatory requirements for USA and Europe.
Gordon has a PhD in bio-electronic technology and a degree in Chemistry.
Read the article about Dr Sanghera in the Financial Times.
Dr Spike Willcocks
Chief BD Officer
After completing an MA in Chemistry and a DPhil in Biochemistry at the University of Oxford, Dr Willcocks became one of the initial members of IPGroup Plc following its landmark deal with the Chemistry Department at Oxford. Ultimately leading the Life Science team, Dr Willcocks' role encompassed all aspects of technology commercialisation, including spin-out company formation and business and corporate development, as well as private and public equity financings.
Dr Willcocks was a key player in the creation of 14 life science businesses based on technology from three universities, leading proposals for the investment of £4m in seed financing from IPGroup and holding positions of Director and Chairman for 6 portfolio companies. Working alongside the executive teams of the portfolio companies, Dr Willcocks played an integral role in out-licensing transactions, co-development deals and acquisitions. As well as supporting fundraisings for portfolio biotechnology companies, raising an aggregate of £20m, Dr Willcocks also assisted with IPGroup's own IPO in October 2003 on the LSE, raising £30m and capitalising the company at over £100m. Dr Willcocks was actively involved in the establishment of ONL whilst at IPGroup before joining full time in January 2006.
He is also a leading real tennis player, and regularly competes in international tournaments.
Chief Technology Officer
Clive Brown is CTO of Oxford Nanopore, where he leads the innovation of breakthrough technologies and product development, that are designed to enable the analysis of anything, by anyone, anywhere.
Clive has held a variety of roles in Genomics and Genetic R&D, he also played a key role in developing the Solexa NGS platform that is now the basis for Illumina’s sequencing technology.
A Chartered Accountant and operations specialist, Tim was interim Finance Director at Oxford Nanopore for several months in 2009, handing over a stable and well documented finance infrastructure. He then joined Oxford Nanopore as Commercial Operations Director in 2012.
In his first five years at the company Tim was responsible for setting up and managing operations and infrastructure across the company, including leading on operations for our first product launch – the MinION Access Programme – in 2015.
As part of his Operations role, Tim selected and implemented our Enterprise Resource Planning system which has remained robust and fit for purpose throughout the company's rapid growth and development.
Tim was appointed as VP-Finance in 2017 and continues to ensure that Oxford Nanopore’s values of agility and entrepreneurialism are reflected in our corporate governance, risk control and business processes, to maximise business efficiency.
Having qualified as an accountant at Ernst & Young, Tim became Financial Controller of Celltech Group plc where he was a key member of the IPO team and managed several transactions of the Listed company. He went on to co-found Sterilox and ran the finance function before joining Clipper Ventures plc as Finance Director. Tim has also been Finance Director at British Biotech plc (Vernalis plc) as well as managing a portfolio of biotech and technology companies, including the AIM-listed Bioventix plc, before joining Oxford Nanopore.